We have observed
9 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 22, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
METHODS AND KITS TO DETECT HEREDITARY ANGIOEDEMA TYPE III
GENETIC PRODUCTS WHICH ARE DIFFERENTIALLY EXPRESSED IN TUMOURS AND USE THEREOF
METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
MONOCLONAL ANTI-GT468 ANTIBODIES FOR TREATMENT OF CANCER
MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER
COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS
DIFFERENTIAL IN TUMOUR GENE PRODUCTS AND USE OF SAME